Michael Barbella, Managing Editor04.27.22
ORHub Inc. and PUR Biologics LLC are now one company. The former has purchased the latter;, though neither company disclosed the deal's terms.
The acquisition enables ORHub to enter the global medical device market, expected to reach $445.1 billion by 2026. With the top U.S. orthopedic sectors of hip, knee, and spine reaching $75 billion, ORHub will leverage PUR's proprietary technologies to regenerate cartilage, mitigate pain, and address the biological causes of degenerative disc disease and osteoarthritis of joints.
"We plan to offer improved treatments for age-related joint pain and the degeneration of cartilage in orthopedic indications. Technologies like PUR's can enable new ways to address the underlying cause of undesired inflammation and pain signals, while igniting our body's natural healing capabilities," said CJ Wiggins, founder, executive board chairman, president, and CEO of ORHub. "We are excited about this acquisition and the opportunity to advance autologous cell and cellular derived therapeutics for osteoarthritis and degenerative disc disease."
With this addition to ORHub, plans are being made to update the corporate branding and ticker symbol to encompass its Digital Technology and Regenerative Therapeutic division as it continues its preparations for an audit and up- listing.
"PUR Biologics has cultivated innovative technologies, in addition to our full line of bone regeneration products currently on the market. We have identified and secured intellectual property that will finally address major gaps in medical treatment. ORHub is the ideal acquisition partner, with both the necessary science and business structure to take our technologies to the global market," explained Ryan Fernan, former CEO of PUR Biologics.
ORHub Inc. is headquartered in Irvine, Calif. The company is focused on the Internet of Things (IoT), creating intelligent automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHub's solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.
The acquisition enables ORHub to enter the global medical device market, expected to reach $445.1 billion by 2026. With the top U.S. orthopedic sectors of hip, knee, and spine reaching $75 billion, ORHub will leverage PUR's proprietary technologies to regenerate cartilage, mitigate pain, and address the biological causes of degenerative disc disease and osteoarthritis of joints.
"We plan to offer improved treatments for age-related joint pain and the degeneration of cartilage in orthopedic indications. Technologies like PUR's can enable new ways to address the underlying cause of undesired inflammation and pain signals, while igniting our body's natural healing capabilities," said CJ Wiggins, founder, executive board chairman, president, and CEO of ORHub. "We are excited about this acquisition and the opportunity to advance autologous cell and cellular derived therapeutics for osteoarthritis and degenerative disc disease."
With this addition to ORHub, plans are being made to update the corporate branding and ticker symbol to encompass its Digital Technology and Regenerative Therapeutic division as it continues its preparations for an audit and up- listing.
"PUR Biologics has cultivated innovative technologies, in addition to our full line of bone regeneration products currently on the market. We have identified and secured intellectual property that will finally address major gaps in medical treatment. ORHub is the ideal acquisition partner, with both the necessary science and business structure to take our technologies to the global market," explained Ryan Fernan, former CEO of PUR Biologics.
ORHub Inc. is headquartered in Irvine, Calif. The company is focused on the Internet of Things (IoT), creating intelligent automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHub's solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.
